



COPY OF PAPERS
ORIGINALLY FILED

USC
B2
S



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Aerts et al.

Serial No.: 10/004,219

Filed: November 2, 2001

For: A MAMMALIAN MUCINASE, ITS
RECOMBINANT PRODUCTION, AND ITS
USE IN THERAPY OR PROPHYLAXIS
AGAINST DISEASES IN WHICH MUCUS
IS INVOLVED OR INFECTIOUS DISEASE

Examiner: To be assigned

Group Art Unit: 1645

Attorney Docket No.: 2183-5136US

CERTIFICATE OF MAILING

I hereby certify that this correspondence along with any attachments referred to or identified as being attached or enclosed is being deposited with the United States Postal Service as First Class Mail on the date of deposit shown below with sufficient postage and in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

8-1-2002
Date

Betty Vowles
Signature

Betty Vowles
Name (Type/Print)

RESPONSE TO NOTICE TO COMPLY

Commissioner for Patents
Washington, D.C. 20231

Sir:

Enclosed is a copy of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence, along with the following required items in connection with the above-referenced application: Copy of the sequence listing in computer readable format (CRF) and statement Under 37 C.F.R. §§ 1.821 through 1.825 (2 pages). This document is being filed within two (2) months from the mailing date of the Notice to Comply.

Please note that the date inserted after the heading "Current Filing Date" was modified. As initially submitted, the Current Filing Date stated November 2, 2001, the filing date of the present application. The date was modified in the Error Report to state June 3, 2002, the date that the Sequence Listing was submitted. It is Applicants' belief that the date which is required following the "Current Filing Date" heading is the date on which the application was filed, not that on which the Sequence Listing was submitted. As such, Applicants have maintained the date following this heading as November 2, 2001. If this belief is in error, please so inform the undersigned.

If any questions remain regarding this matter, please contact the undersigned at the address or telephone number given herein.

Respectfully submitted,



Tawni L. Wilhelm
Registration No. 47,456
Attorney for Applicants
TRASKBRITT, PC
P. O. Box 2550
Salt Lake City, Utah 84110-2550
Telephone: (801) 532-1922

Date: July 31, 2002

ACT/TLW/bv

Enclosures:

Copy of Notice to Comply
Statement Under 37 C.F.R. §§ 1.821 through 1.825 (2 pages)
Sequence listing in computer readable form (CRF)



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/004,219	11/02/2001	Johannes Maria Franciscus Gerardus Aerts	5136US

TRASK, BRITT, & ROSSA
P.O. Box 2550
Salt Lake City, UT 84110



CONFIRMATION NO. 6939

FORMALITIES LETTER



OC00000008381143

Date Mailed: 07/01/2002

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE



COPY OF PAP
ORIGINALLY FILED

#9
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Aerts et al.

Serial No.: 10/004,219

Filed: November 2, 2001

For: A MAMMALIAN MUCINASE, ITS RECOMBINANT PRODUCTION, AND ITS USE IN THERAPY OR PROPHYLAXIS AGAINST DISEASES IN WHICH MUCUS IS INVOLVED OR INFECTIOUS DISEASE

Examiner: To be assigned

Group Art Unit: 1645

Attorney Docket No.: 2183-5136US

CERTIFICATE OF MAILING

I hereby certify that this correspondence along with any attachments referred to or identified as being attached or enclosed is being deposited with the United States Postal Service as First Class Mail (under 37 C.F.R. § 1.8(a)) on the date of deposit shown below with sufficient postage and in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

August 1, 2002
Date of Deposit

Betty Howles
Signature of registered practitioner or other person having reasonable basis to expect mailing to occur on date of deposit shown pursuant to 37 C.F.R. § 1.8(a)(1)(ii)

Betty Howles
Typed/printed name of person whose signature is contained above

Statement under 37 C.F.R. §§ 1.821(f) & (g)

Commissioner for Patents
Washington, D.C. 20231


Sir:

I, Tawni L. Wilhelm, an attorney registered to practice before the United States Patent & Trademark Office and attorney of record for this application, state that:

1. The enclosed paper copy of the SUBSTITUTE SEQUENCE LISTING, as well as the enclosed copy of the SUBSTITUTE SEQUENCE LISTING in computer readable form (CRF), are in compliance with the requirements of 37 C.F.R. §§ 1.822 and/or 1.823.
2. The enclosed copy the SUBSTITUTE SEQUENCE LISTING in computer readable form (CRF) is believed to be identical to the paper copy of the SUBSTITUTE SEQUENCE LISTING.

3. The SUBSTITUTE SEQUENCE LISTING submitted herewith is believed to contain no "new matter" with regard to the referenced application. Modifications have been made in response to the Notice to Comply. Such modifications include the addition of line indicators where inadvertently left out and correction to amino acid numbering in SEQ ID NO:2.

Respectfully submitted,



Tawni L. Wilhelm
Registration No. 47,456
Attorney for Applicants
TRASK BRITT, PC
P. O. Box 2550
Salt Lake City, Utah 84110
Telephone: (801) 532-1922

Date: July 31, 2002